5 Key Takeaways

• 1

  Clobetasol propionate ophthalmic suspension 0.05% may effectively control inflammation and pain after cataract surgery.

• 2

  In Phase 3 trials, clobetasol showed rapid reductions in postoperative inflammation and ocular pain compared to placebo.

• 3

  Patients treated with clobetasol achieved better visual acuity recovery by day eight post-surgery than those receiving placebo.

• 4

  The treatment demonstrated a safety profile comparable to placebo, with no significant intraocular pressure increases.

• 5

  Clobetasol's nanoparticle formulation improves ocular penetration and ease of use, particularly for elderly patients.